S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
Log in
NASDAQ:RARE

Ultragenyx Pharmaceutical Short Interest Ratio and Short Volume

$139.84
+3.59 (+2.63 %)
(As of 02/26/2021 02:13 PM ET)
Add
Compare
Today's Range
$135.21
Now: $139.84
$141.19
50-Day Range
$133.09
MA: $146.21
$167.73
52-Week Range
$31.99
Now: $139.84
$179.65
Volume9,148 shs
Average Volume468,160 shs
Market Capitalization$9.36 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.19

Short Interest

Ultragenyx Pharmaceutical (NASDAQ:RARE) Short Interest Data

Current Short Volume5,330,000 shares
Previous Short Volume5,510,000 shares
Change Vs. Previous Month:-3.27%
Dollar Volume Sold Short$891.28 million
Short Interest Ratio / Days to Cover11.0
Last Record DateJanuary, 29 2021
Outstanding Shares57,470,000 shares
Percentage of Shares Shorted7.96%
Today's Trading Volume9,148 shares
Average Trading Volume468,160 shares
Today's Volume Vs. Average-98.05%

Short Interest Over Time


Ultragenyx Pharmaceutical (NASDAQ:RARE) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/29/20215,330,000 shares $891.28 million -3.3%N/A11.3 $167.22
1/15/20215,510,000 shares $774.71 million -5.3%N/A10.1 $140.60
12/31/20206,300,000 shares $892.96 million -4.1%N/A14.2 $141.74
12/15/20206,300,000 shares $850.44 million -4.1%N/A14.2 $134.99
11/30/20206,570,000 shares $1.10 billion -4.0%N/A15.4 $168.04
11/15/20206,840,000 shares $810.81 million -3.3%N/A16.4 $118.54
10/30/20207,070,000 shares $828.75 million -4.3%N/A17.4 $117.22
10/15/20207,390,000 shares $720.08 million +5.4%13.2%22.3 $97.44
9/30/20207,010,000 shares $682.21 million +1.7%12.5%20.3 $97.32
9/15/20206,890,000 shares $565.46 million +1.6%12.3%16.9 $82.07
8/31/20206,780,000 shares $513.86 million -0.9%12.1%15.7 $75.79
8/14/20206,840,000 shares $562.93 million -14.7%12.2%15.2 $82.30
7/31/20208,020,000 shares $706.88 million No Change14.3%16.1 $88.14
7/15/20208,020,000 shares $626.84 million +4.6%14.5%15.2 $78.16
6/30/20207,670,000 shares $596.50 million +3.4%13.7%13.7 $77.77
6/15/20207,420,000 shares $628.03 million -2.2%13.3%13.5 $84.64
5/29/20207,590,000 shares $558.02 million +0.8%13.6%13 $73.52
5/15/20207,530,000 shares $515.50 million +1.4%13.5%12.7 $68.46
4/30/20207,430,000 shares $528.35 million No Change13.3%13.1 $71.11
4/15/20207,430,000 shares $500.48 million -1.1%13.5%13.7 $67.36
3/31/20207,510,000 shares $497.39 million +8.1%13.6%12.5 $66.23
3/13/20206,949,400 shares $364.84 million +6.9%12.8%14.5 $52.50
2/28/20206,500,000 shares $247.85 million +1.4%12.0%12.7 $38.13
2/14/20206,410,000 shares $315.24 million -4.2%11.8%11.9 $49.18
1/31/20206,690,000 shares $372.70 million +4.0%12.5%12.2 $55.71

Ultragenyx Pharmaceutical (NASDAQ:RARE) Short Interest FAQ

speech bubbles
speech bubbles











What is Ultragenyx Pharmaceutical's current short interest?

Short interest is the volume of Ultragenyx Pharmaceutical shares that have been sold short but have not yet been closed out or covered. As of January 29th, traders have sold 5,330,000 shares of RARE short.

What is a good short interest ratio for Ultragenyx Pharmaceutical?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Ultragenyx Pharmaceutical currently has a short interest ratio of 11.0.

Is Ultragenyx Pharmaceutical's short interest increasing or decreasing?

Ultragenyx Pharmaceutical saw a decline in short interest in January. As of January 29th, there was short interest totaling 5,330,000 shares, a decline of 3.3% from the previous total of 5,510,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Ultragenyx Pharmaceutical's short interest compare to its competitors?

0.00% of Ultragenyx Pharmaceutical's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Ultragenyx Pharmaceutical: Alexion Pharmaceuticals, Inc. (2.00%), Astellas Pharma Inc. (0.00%), Shiseido Company, Limited (0.00%), BeiGene, Ltd. (0.00%), Genmab A/S (0.00%), MERCK Kommanditgesellschaft auf Aktien (0.00%), Genmab A/S (0.00%), UCB SA (0.00%), Horizon Therapeutics Public Limited (0.00%), and Catalent, Inc. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon Plc ($5.34 billion), Charter Communications, Inc. ($5.03 billion), ViacomCBS Inc. ($4.99 billion), DuPont de Nemours, Inc. ($4.72 billion), Analog Devices, Inc. ($4.57 billion), Snap Inc. ($3.87 billion), Moderna, Inc. ($3.58 billion), Futu Holdings Limited ($2.75 billion), Snowflake Inc. ($2.43 billion), and Palantir Technologies Inc. ($2.18 billion). View all of the most shorted stocks.

What does it mean to sell short Ultragenyx Pharmaceutical stock?

Short selling RARE is an investing strategy that aims to generate trading profit from Ultragenyx Pharmaceutical as its price is falling. Ultragenyx Pharmaceutical's stock is trading up $3.59 today. To short Ultragenyx Pharmaceutical stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Ultragenyx Pharmaceutical will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Ultragenyx Pharmaceutical?

A short squeeze for Ultragenyx Pharmaceutical occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RARE, which in turn drives the price of the stock up even further.

How often is Ultragenyx Pharmaceutical's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RARE, twice per month. The most recent reporting period available is January, 29 2021.



This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.